{"id":"3f710d5a-33ff-57ed-b69b-93bebf6ef0b3","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-combined-lcms-null","predicate":"no_detected_change_in_recorded_comparison","statement":"The smaller LC-MS subset did not show a statistically significant NAD+ treatment effect in the same human trial.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"413ff6e5-c6be-54c3-b9d7-35b585dfc7c2","mechanism_event_label":"The smaller LC-MS subset did not show a statistically significant NAD+ treatment effect in the same human trial.","subject":{"id":"3b9d39d2-dcd2-5453-b25f-2ec41fc3f10b","slug":"nuchido-time-plus-2024","display_name":"Nuchido TIME+ multicomponent preparation in the 2024 trial","entity_type_key":"chemical_species"},"object":{"id":"6a1be942-8261-5ba7-9d98-2a50c0d51fc3","slug":"circulating-nad-content","display_name":"Circulating NAD content","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"413ff6e5-c6be-54c3-b9d7-35b585dfc7c2","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-combined-lcms-null-event","event_type":"experimental_observation","label":"The smaller LC-MS subset did not show a statistically significant NAD+ treatment effect in the same human trial.","description":"### api-human-combined-lcms-null\n\nThe smaller LC-MS subset did not show a statistically significant NAD+ treatment effect in the same human trial.\nMatched reduction of the main assay sample also lost significance. Sample size, selection, storage and assay identity limit comparison.\nModel and exposure: Seventeen-person subset; stored samples and missing participants.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: The use of a systems approach to increase NAD<sup>+</sup> in human participants. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"3b9d39d2-dcd2-5453-b25f-2ec41fc3f10b","slug":"nuchido-time-plus-2024","display_name":"Nuchido TIME+ multicomponent preparation in the 2024 trial","entity_type_key":"chemical_species"},"role":"tested factor","stoichiometry":null,"state_label":"Multicomponent preparation","sequence_order":0,"notes":""},{"entity":{"id":"6a1be942-8261-5ba7-9d98-2a50c0d51fc3","slug":"circulating-nad-content","display_name":"Circulating NAD content","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"no_detected_change","sequence_order":1,"notes":""},{"entity":{"id":"283ed24b-06a1-50aa-9281-df3bac6ce37e","slug":"nad-plus","display_name":"NAD+","entity_type_key":"small_molecule"},"role":"LC-MS analyte","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Multicomponent preparation\", \"comparator\": \"Baseline and placebo comparisons reported by the study\", \"endpoint\": \"The smaller LC-MS subset did not show a statistically significant NAD+ treatment effect in the same human trial.\", \"effect_direction\": \"no_detected_change\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Seventeen-person subset; stored samples and missing participants.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The smaller LC-MS subset did not show a statistically significant NAD+ treatment effect in the same human trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"The use of a systems approach to increase NAD<sup>+</sup> in human participants. | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-human-combined-lcms-null; Matched reduction of the main assay sample also lost significance. Sample size, selection, storage and assay identity limit comparison.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"91152280-e342-5719-856d-206335878124","evidence_kind":"source_excerpt","locator":"Lines 500-506","start_line":500,"end_line":506,"excerpt":"### api-human-combined-lcms-null\n\nThe smaller LC-MS subset did not show a statistically significant NAD+ treatment effect in the same human trial.\nMatched reduction of the main assay sample also lost significance. Sample size, selection, storage and assay identity limit comparison.\nModel and exposure: Seventeen-person subset; stored samples and missing participants.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: The use of a systems approach to increase NAD<sup>+</sup> in human participants. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Seventeen-person subset; stored samples and missing participants.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[{"id":"f7ebf94f-9d22-57e5-83a8-2d33fd8a5b0b","relation_type":"limits_scope_of","notes":"Distinct assays and unequal sample subsets limit a single confident quantitative NAD+ claim.","source_claim_id":"3f710d5a-33ff-57ed-b69b-93bebf6ef0b3","source_claim_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-combined-lcms-null","source_statement":"The smaller LC-MS subset did not show a statistically significant NAD+ treatment effect in the same human trial.","target_claim_id":"b3f28d87-f892-56a5-b7d6-68b5732de4fb","target_claim_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-combined-nad","target_statement":"The 2024 multicomponent trial reported a 26.5% increase from baseline at day 28 in its main whole-blood NAD assay."}],"conflicts":[],"corrections":[],"research":null}